+

WO1991000745A1 - Procede de production d'une surface biocompatible - Google Patents

Procede de production d'une surface biocompatible Download PDF

Info

Publication number
WO1991000745A1
WO1991000745A1 PCT/AU1990/000292 AU9000292W WO9100745A1 WO 1991000745 A1 WO1991000745 A1 WO 1991000745A1 AU 9000292 W AU9000292 W AU 9000292W WO 9100745 A1 WO9100745 A1 WO 9100745A1
Authority
WO
WIPO (PCT)
Prior art keywords
phospholipid
coated
blood
solvent
bath
Prior art date
Application number
PCT/AU1990/000292
Other languages
English (en)
Inventor
Brian Andrew Hills
Original Assignee
Macnaught Pty Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macnaught Pty Limited filed Critical Macnaught Pty Limited
Priority claimed from AU59502/90A external-priority patent/AU631903B2/en
Publication of WO1991000745A1 publication Critical patent/WO1991000745A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0041—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment

Definitions

  • the present invention relates to methods for producing biocompatible surfaces by coating them with phospholipid and binding the phospholipid to the surface by means of ultrasonication.
  • the formation of blood clots on the surfaces of these instruments is dangerous and may prove fatal if the clots are washed off by the blood flow into the vascular system.
  • US Patent 4 426 330 discloses a chemically modified phospholipid for more stable coatings.
  • US Patent 4 438 329 discloses a phospholipid chemically bonded to a polymer for coating surfaces.
  • the introduction of new, chemically modified phospholipids into a human body or blood stream may have unforseen - 2 -
  • the present invention concerns a method for producing a biocompatible surface, by coating the surface with phospholipid characterised by immersing the surface to be coated in a bath containing a suspension of phospholipid in a liquid in which it is sparingly soluble, and then ultrasonicating the bath to coat the surface with phospholipid.
  • Another aspect of the invention concerns pre-treating the surface to be coated.
  • the surface is firstly immersed in a phospholipid solution.
  • the solution comprises phospholipid substantially dissolved in a solvent in which it is soluble, such as ethanol or chloroform.
  • the surface is then removed from the solution and the solvent allowed to evaporate off.
  • the dry surface is then subjected to the ultrasonication process described above.
  • Any suitable surface may be coated, such as metal, glass, plastics or ceramics. Any phospholipid may be used and some examples are described in Table 1. TABLE 1
  • Phosphoglycerides phosphatidic acids cytidylic phosphoglycerides (CDP diglyceride) choline phosphoglycerides ethanolamine phosphoglycerides
  • Phosphoglycolipids diacyl glycerylphosphoryldiglucosyl
  • Phosphodiol lipids acyl dihydroxyacetone phosphate alkyl dihydroxyacetone phosphate
  • the preferred phospholipid is phosphatidylcholine, (lecithin) .
  • the ultrasonic treatment is conducted in the normal manner using commercially available ultrasonic equipment. - 4 - '
  • the suspension of phospholipid used in the bath comprises preferably finely divided phospholipid suspended in a liquid in which it is only sparingly soluble.
  • the suspension is preferably an aqueous suspension.
  • Phospholipid is added to the suspension in solid form and is suspended by an initial ultrasonication to form liposomes.
  • the phospholipid is preferably suspended at a concentration of 0.1 to 10% w/v, most preferably 1 to 2% w/v.
  • the liquids that may be used to suspend the phospholipid in accordance with the present invention include water and physiological saline solutions.
  • Any ultrasound device can be used in accordance with the present invention, such as the Model G112SPIT (serial No. 11254) produced by Laboratory Supplies Co. Inc., New York.
  • the method of coating a surface with phospholipid may also comprise a pre-treatment step, which involves dissolving phospholipid in a solvent; placing the surface to be coated into the phospholipid/solvent solution to allow initial gross deposition of phospholipid onto the surface; removing the coated surface from the phospholipid solvent solution; evaporating off residual solvent on the coated surface; placing the coated surface into the suspension; and ultrasonicating the coated surface as described previously.
  • a pre-treatment step which involves dissolving phospholipid in a solvent; placing the surface to be coated into the phospholipid/solvent solution to allow initial gross deposition of phospholipid onto the surface; removing the coated surface from the phospholipid solvent solution; evaporating off residual solvent on the coated surface; placing the coated surface into the suspension; and ultrasonicating the coated surface as described previously.
  • the phospholipid is suspended in the solvent by stirring. Any solvent that dissolves phospholipid may be used in accordance with the present invention, such as chloroform or methanol.
  • the pre-treatment by immersion in the dissolved phospholipid may involve the gross deposition of phospholipid from a solution with a low degree of supersaturation.
  • the ultrasonication of the coated surface orientates and consolidates the phospholipid that was deposited on the surface to be coated from the solution.
  • the slow deposition of the phospholipid from the solution with a low degree of supersaturation onto the surface to be coated enables the phospholipid to be deposited with a better orientation and thus gives an effective coating.
  • the methods of the present invention enable the rapid and successful coating of surfaces with phospholipid.
  • the methods may be used to coat the surfaces of medical instruments, thereby making the surfaces non-thrombogenic.
  • the present invention is particularly applicable for the production of coated catheters for which the surfactant properties of lubrication and release are ideal. It may also be used to produce pacemakers and prosthetic devices which are less likely to be rejected by the body's immune system. The invention may also be applied to ceramic prosthesis to reduce their permeability.
  • the present invention has found that surfaces having phospholipid adhered to them seem to be less likely to generate an antibody response than uncoated materials. Similarly, the formation of blood clots is greatly reduced on such coated surfaces.
  • heparin which can now be grafted to certain surfaces to render then non-thrombogenic.
  • One of the features of grafted heparin is the number of negative charges which they impart, indicating that they might function by providing a site most conducive to the adsorption of the endogenous surfactants, such as phospholipids, which are then the true interface with blood or other body fluids.
  • the experiment was performed by solvent depositing soya lecithin in chloroform. Whilst these rods showed less clotting than the uncoated control rod, they were found to be less effective than the rods of comparative example 1 and markedly less effective than the rods coated using ultrasound..
  • Example 2 The Experiments 2 and 3 were repeated, but the surfaces were allowed to dry before being placed in the bath and ultrasonicated as described in Example 1. The glass rods resulting were placed in blood as described in Example 1. The rods thus treated were clean of blood, amd the incidence of clotting was less than in Example 2 or 3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Les procédés décrits, qui permettent de produire des surfaces biocompatibles, consistent à recouvrir ces surfaces d'un phospholipide et à faire adhérer le phospholipide sur la surface au moyen d'une technique de soudage aux ultrasons.
PCT/AU1990/000292 1989-07-07 1990-07-06 Procede de production d'une surface biocompatible WO1991000745A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPJ5139 1989-07-07
AUPJ513989 1989-07-07
AU59502/90A AU631903B2 (en) 1989-07-07 1990-07-06 A method for producing a biocompatible surface

Publications (1)

Publication Number Publication Date
WO1991000745A1 true WO1991000745A1 (fr) 1991-01-24

Family

ID=25632425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1990/000292 WO1991000745A1 (fr) 1989-07-07 1990-07-06 Procede de production d'une surface biocompatible

Country Status (2)

Country Link
EP (1) EP0486625A1 (fr)
WO (1) WO1991000745A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006719A1 (fr) * 1990-10-22 1992-04-30 Biocompatibles Limited Surfaces non-thrombogenes
WO1992021386A1 (fr) * 1991-06-07 1992-12-10 Biocompatibles Limited Couche de revetement polymere
EP0554869A1 (fr) * 1992-02-07 1993-08-11 Paradigm Biotechnologies Partnership Biomatériaux à biocompatibilité améliorée
WO1993021970A1 (fr) * 1992-04-24 1993-11-11 Biocompatibles Limited Procede pour diminuer l'adherence de micro-organismes
EP0746266A1 (fr) * 1992-07-27 1996-12-11 Smith & Nephew, Inc. Elements cardiaques artificiels pourvus d'un revetement biocompatible ameliore
US5798117A (en) * 1992-04-24 1998-08-25 Biocompatibles Limited Method of reducing microorganism adhesion
WO1999000153A1 (fr) * 1997-06-30 1999-01-07 Becton Dickinson And Company Lubrifiant contenant de la lecithine pour instrument medical
WO2001015752A1 (fr) * 1999-08-31 2001-03-08 Destiny Pharma Limited Implants enduits de phospholipide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348329A (en) * 1979-12-20 1982-09-07 Dennis Chapman Biocompatible surfaces
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
WO1987002684A1 (fr) * 1985-11-04 1987-05-07 Biocompatibles Limited Plastiques contenant des lipides
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348329A (en) * 1979-12-20 1982-09-07 Dennis Chapman Biocompatible surfaces
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
WO1987002684A1 (fr) * 1985-11-04 1987-05-07 Biocompatibles Limited Plastiques contenant des lipides
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biochem. Soc. Trans., Vol. 17, No. 6, published 1989, D. CHAPMAN and P.I. HARIS "Biomembrane structures. Fourier transform infrared spectroscopy and biomembrane technology", pages 951-3. *
Prog. Clin. Biol. Res,. Vol. 292, published 1989, D. CHAPMAN et al. "Biomembranes: basic science and future technology" pages 3-12. *
See also references of EP0486625A4 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006719A1 (fr) * 1990-10-22 1992-04-30 Biocompatibles Limited Surfaces non-thrombogenes
US6521283B1 (en) 1990-10-22 2003-02-18 Biocompatibles Limited Non-thrombogenic surfaces
WO1992021386A1 (fr) * 1991-06-07 1992-12-10 Biocompatibles Limited Couche de revetement polymere
US5496581A (en) * 1991-06-07 1996-03-05 Biocompatibles Limited Polymeric coating
EP0554869A1 (fr) * 1992-02-07 1993-08-11 Paradigm Biotechnologies Partnership Biomatériaux à biocompatibilité améliorée
AU675063B2 (en) * 1992-04-24 1997-01-23 Biocompatibles Uk Limited Method of reducing microorganism adhesion
US5798117A (en) * 1992-04-24 1998-08-25 Biocompatibles Limited Method of reducing microorganism adhesion
WO1993021970A1 (fr) * 1992-04-24 1993-11-11 Biocompatibles Limited Procede pour diminuer l'adherence de micro-organismes
EP0746266A1 (fr) * 1992-07-27 1996-12-11 Smith & Nephew, Inc. Elements cardiaques artificiels pourvus d'un revetement biocompatible ameliore
EP0746266A4 (fr) * 1992-07-27 1999-08-18 Smith & Nephew Richards Inc Elements cardiaques artificiels pourvus d'un revetement biocompatible ameliore
WO1999000153A1 (fr) * 1997-06-30 1999-01-07 Becton Dickinson And Company Lubrifiant contenant de la lecithine pour instrument medical
WO2001015752A1 (fr) * 1999-08-31 2001-03-08 Destiny Pharma Limited Implants enduits de phospholipide
US6863693B2 (en) 1999-08-31 2005-03-08 Destiny Pharma Limited Phospholipid-coated implants

Also Published As

Publication number Publication date
EP0486625A1 (fr) 1992-05-27
EP0486625A4 (fr) 1992-04-01

Similar Documents

Publication Publication Date Title
US4749585A (en) Antibiotic bonded prosthesis and process for producing same
US5496581A (en) Polymeric coating
US5840387A (en) Sulfonated multiblock copolymer and uses therefor
US4879135A (en) Drug bonded prosthesis and process for producing same
JP2648426B2 (ja) 生物適合性表面を有する物品
US5711959A (en) Biocompatible materials
WO2008122034A1 (fr) Procédé pour préparer un substrat revêtu d'une biomolécule
WO1991000745A1 (fr) Procede de production d'une surface biocompatible
EP0554302B1 (fr) Surfaces non-thrombogenes
Ai et al. Gelatin-glutaraldehyde cross-linking on silicone rubber to increase endothelial cell adhesion and growth
Krishna et al. Covalently grafted phospholipid monolayer on silicone catheter surface for reduction in platelet adhesion
AU5950290A (en) A method for producing a biocompatible surface
JPH0236267B2 (fr)
KR102131101B1 (ko) 선택적 플라즈마 에칭법에 의한, 혈액적합성이 향상된 ePTFE 인공혈관의 제조방법
Whalen et al. A new method of in vivo screening of thromboresistant biomaterials utilizing flow measurement
Ishihara Biomimetic polymers with phosphorylcholine groups as biomaterials for medical devices
CN114522278A (zh) 一种长效抗凝血涂层及其制备方法
JP3509829B2 (ja) 抗凝血材料
JPH10151192A (ja) 抗血栓性組成物および医用材料
JPH07108061A (ja) 抗血栓性複合体および医療用器具
JP3700440B2 (ja) 抗血栓性医療用具およびその製造方法
WO2020230925A1 (fr) Procédé de fabrication de vaisseaux sanguins artificiels en eptfe présentant une meilleure hémocompatibilité par gravure sélective au plasma
SU745518A1 (ru) Антитромбогенный материал
Nakabayashi Preparation of biocompatible materials and their evaluation
Mazzucotelli et al. The superiority of hollow fiber membrane over bubble oxygenator in a perfusion circuit for the evaluation of small caliber endothelialized arterial prostheses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1990917894

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1990917894

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1990917894

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载